Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals.
BACKGROUND
Ghrelin is a growth hormone-releasing acylated peptide found to be an appetite stimulant and low levels of it are detected in cachexia. The aim of the present study was to investigate the plasma ghrelin levels in cancer patients with a low performance status and weight loss and compare them with those of healthy individuals without weight loss.


METHODS
Thirty patients (median age 65 years) with different malignancies, mainly pancreatic and gastric, and 27 healthy individuals (median age 62 years) were examined. The gender of both groups was well balanced. Plasma ghrelin was measured by a radioimmunoassay kit that uses a polyclonal antibody which recognizes the C-terminal of ghrelin.


RESULTS
There was a statistically significant difference in the plasma ghrelin levels of the patients vs. the controls, with the patients having much lower levels (p<0.001).


CONCLUSIONS
The notable reduction of ghrelin levels might be due to the severity and progression of the disease.
Department of Endocrinology and Metabolism, Errikos Dunant Hospital, Athens, Greece.
Ioannis
I
Legakis
John
J
Stathopoulos
Timos
T
Matzouridis
George P
GP
Stathopoulos
D000368:Aged; D002100:Cachexia / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D010190:Pancreatic Neoplasms / Q000097:blood; D013274:Stomach Neoplasms / Q000097:blood; D015431:Weight Loss
D054439:Ghrelin